Recent Pfizer Press Releases

  • 5/7/19 7:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA® (lorlatinib, available in the U.S., Canada and Japan under the brand name LORBRENA®), as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as themore...
  • 5/6/19 6:45 am EDT

    — First and only medicines approved for patients with either wild-type or hereditary transthyretin amyloid cardiomyopathy —

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL ® (tafamidis meglumine) and VYNDAMAX™ (tafamidis) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are two oral formulations of the first-more...
  • 4/30/19 6:45 am EDT
    • First-Quarter 2019 Revenues of $13.1 Billion, Reflecting 5% Operational Growth Driven by 7% Operational Growth from Pfizer Biopharmaceuticals Group and 1% Operational Growth From Upjohn
    • First-Quarter 2019 Reported Diluted EPS(1) of $0.68, Adjusted Diluted EPS(2) of $0.85
    • Raised Midpoint of 2019 Adjusted Diluted EPS(2) Guidance Range by $0.01 to $2.83 to $2.93, Primarily Reflecting Adjusted Other Income(2) Recorded During First-Quarter 2019, Partially Offset by the Unfavorable Impact of Foreign Exchange
    • Reaffirmed 2019 Financial Guidance for Revenues
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS(2). At the start of the 2019 fiscal year(3), Pfizer reorganized its commercial operations into three businesses: Pfizer Biopharmaceuticals Group (Biopharma), a science-based innovative medicines business, which includes all of the previousmore...
  • 4/26/19 11:00 am EDT

    Positive opinion based on results from largest Phase 3 trial performed to date of a PARP inhibitor in gBRCA-mutated advanced breast cancer

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, be granted marketing authorization in the European Union (EU). The indication the CHMP adopted is for TALZENNA as monotherapy for the treatment of adult patients withmore...
  • 4/25/19 11:17 am EDT

    Declares 36-Cent Second-Quarter 2019 Dividend

    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 36-cent second-quarter 2019 dividend on the company’s common stock, payable June 7, 2019 to shareholders of record at the close of business on May 10, 2019. The second-quarter 2019 cash dividend will be the 322nd consecutive quarterly dividend paid by Pfizer. “In 2018, we estimate that we reached more than 784 million people with our products,” stated Albertmore...
  • 4/18/19 5:05 pm EDT
    NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. The tanezumab 5 mg treatmentmore...
  • 4/18/19 2:00 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.m. Eastern Daylight Time on Thursday, April 25, 2019. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy/ and click on the “Meeting Webcast” button. Pre-registration begins today. A replay of the webcast will be available on www.pfizer.com throughmore...
  • 4/13/19 4:00 am EDT

    The U.S. FDA awarded Breakthrough Therapy Designation for this potential indication based on these Phase 2 data

    - - -

    The Biologics License Application is expected to be submitted to the U.S. FDA by the end of 2020, subject to the successful completion of Phase 3 studies

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes contained in the vaccine in adults aged 18 years and older. The presentation was delivered at the 29th European Congress of Clinical Microbiologymore...
  • 4/4/19 2:57 pm EDT

    Approval of expanded indication based predominately on real-world data

    NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The approval is based on data frommore...
  • 4/3/19 9:42 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO® (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. “Lung cancer remains the leading cause of cancer-related death worldwide andmore...